REPORT OUTLOOK
Market Size | CAGR | Dominating Region |
---|---|---|
USD 22.09 billion by 2030 | 8.5% | North America |
by Indication | by End User |
---|---|
|
Dermatology Clinics |
SCOPE OF THE REPORT
Market Overview
The global atopic eczema treatment market size is projected to grow from USD 12.48 billion in 2023 to USD 22.09 billion by 2030, exhibiting a CAGR of 8.5% during the forecast period.
Treatment for atopic eczema, also known as atopic dermatitis, focuses on alleviating symptoms, reducing inflammation, and preventing flare-ups. This typically involves a combination of approaches. Moisturizers and emollients are crucial for maintaining skin hydration and preventing dryness, which can worsen symptoms. Topical corticosteroids are commonly prescribed during flare-ups to alleviate inflammation and itching. For cases not responding to standard treatments, immunomodulatory like tacrolimus or pimecrolimus may be recommended to suppress the immune response in the skin and manage inflammation. Lifestyle adjustments, such as avoiding triggers like certain fabrics and harsh soaps, are also important in managing the condition. Oral antihistamines may be used to relieve itching and improve sleep quality in some instances. In severe or persistent cases, phototherapy or systemic medications such as oral corticosteroids or immunosuppressant’s may be considered under close medical supervision. Overall, managing atopic eczema requires a personalized approach involving various treatments, lifestyle modifications, and regular monitoring by a healthcare professional.
Treating atopic eczema effectively holds significant importance for various reasons. Primarily, it greatly enhances the quality of life for those grappling with this chronic condition. Atopic eczema often induces severe itching, discomfort, and pain, leading to sleep disturbances and emotional distress. By mitigating symptoms and curtailing flare-ups, treatment aids patients in coping with these challenges and reclaiming normalcy in their daily routines. Additionally, managing atopic eczema is vital for averting complications and secondary infections. The persistent scratching associated with the condition can compromise the skin barrier, rendering it more vulnerable to bacterial, viral, or fungal invasions. By managing inflammation and itching, treatment diminishes the likelihood of such complications, thereby mitigating further aggravation of the condition and accelerating the healing process. Moreover, timely intervention in atopic eczema helps prevent long-term skin damage and scarring. Chronic inflammation and scratching can culminate in thickened, leathery skin in affected areas, known as lichenification. Prompt treatment with suitable measures serves to minimize skin damage, preserving its integrity and appearance. Furthermore, addressing atopic eczema comprehensively may reduce the necessity for more aggressive interventions in the future. By effectively managing symptoms and pre-empting flare-ups, treatment can potentially lessen reliance on systemic medications or invasive procedures, which carry heightened risks of side effects and complications. Lastly, holistic management of atopic eczema can yield broader health benefits. Research suggests a correlation between atopic eczema and other allergic conditions like asthma and hay fever, forming what is known as the atopic march. By effectively managing atopic eczema, there exists a potential to mitigate the risk of developing these comorbidities or alleviate their severity. In essence, the significance of atopic eczema treatment lies in its capacity to enhance quality of life, prevent complications, preserve skin integrity, reduce dependence on systemic treatments, and potentially mitigate the onset of other allergic conditions. This underscores the importance of adopting timely and comprehensive management strategies tailored to the individual needs of patients.
ATTRIBUTE | DETAILS |
Study period | 2020-2030 |
Base year | 2022 |
Estimated year | 2023 |
Forecasted year | 2023-2030 |
Historical period | 2019-2021 |
Unit | Value (USD Billion) |
Segmentation | By Indication, End User and Region |
By Indication |
|
 By End User |
|
Â
By Region  |
|
Atopic Eczema Treatment Market Segmentation Analysis
The global atopic eczema treatment market is divided into three segments, by indication, end user and region. By indication, the market is divided into topical, oral, and injectable. End user divides into hospital pharmacies, retail pharmacies, online pharmacies, drug stores, mail order pharmacies, dermatology clinics and by region the market.
The market for treating atopic eczema is segmented by indication into three main categories: topical, oral, and injectable treatments. Topical treatments encompass creams, ointments, and lotions applied directly to the affected areas of the skin. These formulations often include corticosteroids to reduce inflammation, along with moisturizers to hydrate the skin and relieve dryness. Additionally, topical immunomodulatory, such as tacrolimus or pimecrolimus, may be prescribed to regulate the immune response in the skin. Topical treatments are typically the first line of defense in managing mild to moderate cases of atopic eczema due to their localized application and relatively low risk of systemic side effects. Oral treatments involve medications taken by mouth to address atopic eczema symptoms and underlying inflammation. These may include antihistamines to alleviate itching, oral corticosteroids to reduce inflammation during severe flare-ups, or systemic immunosuppressant has to modulate the immune response. Oral treatments are often prescribed for moderate to severe cases of atopic eczema or when topical therapies have proven ineffective. Injectable treatments are administered via injection and are typically reserved for severe or refractory cases of atopic eczema that do not respond to other forms of treatment. Biologic agents, such as dupilumab, are a newer class of injectable medications that target specific components of the immune system involved in the inflammatory process of atopic eczema. These treatments are usually prescribed under the supervision of a dermatologist or allergist and may require regular monitoring for potential side effects. In summary, the atopic eczema treatment market is divided into topical, oral, and injectable categories, each offering different approaches to managing symptoms and inflammation associated with the condition. The choice of treatment depends on the severity of the eczema, individual patient factors, and the preferences of healthcare providers.
The market for atopic eczema treatments is segmented based on the end-user channels through which consumer’s access medications and therapies. These channels encompass hospital pharmacies, retail pharmacies, online pharmacies, drug stores, mail-order pharmacies, and dermatology clinics. Hospital pharmacies operate within healthcare facilities, providing prescribed medications to patients during their stay or outpatient visits. They play a crucial role in ensuring timely access to appropriate treatments for atopic eczema within medical settings. Retail pharmacies, located in community settings like grocery stores or standalone outlets, cater to the general public’s medication needs, offering both prescription and over-the-counter options. Patients with atopic eczema can conveniently obtain their prescribed treatments from these outlets with personalized support from pharmacists. Online pharmacies offer remote access to medications through digital platforms, allowing individuals to purchase prescribed treatments from their homes and receive deliveries directly. Drug stores, similar to retail pharmacies, provide a variety of prescription and over-the-counter medications, serving as accessible points for individuals seeking treatments for atopic eczema and other health concerns. Mail-order pharmacies specialize in delivering medications via postal services or couriers, providing a convenient option for patients to receive prescribed treatments without visiting physical locations. Dermatology clinics focus on diagnosing and treating skin conditions like atopic eczema, offering comprehensive care such as medical consultations, diagnostic tests, and tailored treatment options. In essence, these end-user channels provide diverse avenues for individuals with atopic eczema to access the medications and support necessary for effective management of their condition.
Atopic Eczema Treatment Market Dynamics
Driver
The rising incidence of atopic eczema globally is a significant driver for the growth of the treatment market.
The escalating prevalence of atopic eczema globally serves as a significant catalyst propelling the growth of the treatment market. Various factors contribute to this surge, including shifts in lifestyle patterns, heightened exposure to environmental pollutants, and inherent genetic susceptibilities. These elements collectively disrupt the skin’s natural defenses, fostering conditions conducive to the onset or exacerbation of atopic eczema. Furthermore, the amalgamation of genetic predispositions with environmental triggers amplifies the susceptibility of certain populations to this condition. Consequently, healthcare systems witness an escalating burden as the prevalence of atopic eczema climbs, fueling the demand for efficacious treatment modalities. With increasing awareness and improved diagnostic capabilities, there is a heightened focus on alleviating symptoms and enhancing patients’ well-being, driving the need for diverse treatment options ranging from topical remedies to advanced biologic interventions.
Restraint
Concerns regarding the safety and tolerability of treatments can restrain market growth.
The use of traditional treatments for atopic eczema, notably topical corticosteroids, often brings about various adverse effects, including skin thinning, irritation, and immunosuppression. Despite their effectiveness in symptom management, these treatments raise significant concerns regarding their safety and tolerability, potentially hindering market expansion. Topical corticosteroids, favored for their anti-inflammatory properties, can inadvertently lead to skin thinning, rendering it more vulnerable to damage and infection. Prolonged or improper application may exacerbate skin irritation, causing discomfort and undermining treatment adherence. Additionally, the immunosuppressive effects of corticosteroids raise concerns about their long-term impact, especially in patients with compromised immune systems or those requiring extended therapy. Such adverse effects instill hesitancy among patients and healthcare providers, driving a quest for alternative treatments with more favorable risk-benefit profiles. Addressing apprehensions surrounding the safety and tolerability of conventional therapies is crucial for developing novel interventions that mitigate adverse effects while preserving efficacy. By addressing these concerns, the atopic eczema treatment market can instill confidence and promote wider acceptance and adoption of therapeutic options among affected individuals.
Opportunities
Advances in precision medicine and genetic profiling offer opportunities for the development of personalized therapies tailored to individual patient characteristics.
The emergence of personalized therapies, driven by advancements in precision medicine and genetic profiling, signifies a groundbreaking frontier in treating atopic eczema. These cutting-edge strategies offer compelling opportunities to customize treatments based on individual patient characteristics, thereby reshaping treatment outcomes and enhancing patient contentment. Precision medicine utilizes extensive genetic and molecular analysis to decipher the underlying factors driving atopic eczema within each patient. By identifying the distinct genetic makeup and molecular signatures associated with the condition, healthcare practitioners can tailor interventions to target specific molecular pathways implicated in disease progression. This personalized approach facilitates the selection of treatments with the highest likelihood of effectiveness while minimizing the risk of adverse effects, ultimately optimizing therapeutic results. Additionally, personalized therapies take into consideration various patient-specific elements, including genetic predispositions, biomarker profiles, and environmental triggers. By integrating these personalized factors, healthcare providers can design treatment plans tailored to meet the individual needs and preferences of each patient. This personalized approach fosters a more patient-centered method of care, promoting better treatment adherence and overall patient satisfaction.
Moreover, personalized therapies hold the potential to enhance therapeutic response rates and reduce treatment failures by matching patients with the most appropriate interventions based on their unique characteristics. This targeted strategy not only maximizes treatment effectiveness but also minimizes healthcare expenses associated with trial-and-error approaches and ineffective treatments. In essence, the advent of personalized therapies represents a transformative shift in managing atopic eczema, offering a precise and tailored approach to treatment that promises to improve outcomes and elevate patient well-being. As precision medicine advances, it stands poised to revolutionize the landscape of atopic eczema treatment, ushering in an era of personalized and optimized care for patients worldwide.
Atopic Eczema Treatment Market Trends
-
Biologic medications, like dupilumab, are gaining prominence for treating moderate to severe atopic eczema. These therapies target specific immune system components involved in inflammation, offering a more precise treatment approach compared to traditional systemic treatments. The market is seeing a surge in research and development efforts toward biologic therapies, with numerous new options in development.
-
Understanding the diverse nature of atopic eczema and its underlying mechanisms is leading to a move toward precision medicine approaches. Customizing treatments based on individual patient characteristics, such as genetic factors, immune responses, and environmental triggers, is becoming increasingly important. This trend is driving the development of personalized treatment strategies and therapies guided by biomarkers.
-
Topical therapies remain fundamental for managing mild to moderate atopic eczema. Innovative topical formulations, including new corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 inhibitors, are entering the market. These formulations offer improved efficacy, safety, and convenience for patients, contributing to growth in the topical treatment segment.
-
The COVID-19 pandemic accelerated the adoption of telemedicine and digital health solutions for remote patient management. Virtual consultations, tele monitoring platforms, and mobile health apps are increasingly used for delivering care, monitoring disease progression, and educating patients about managing atopic eczema. This trend is expected to persist, enhancing accessibility and convenience for patients beyond the pandemic.
-
There is a growing emphasis on patient-centered care and shared decision-making in atopic eczema management. Healthcare providers are involving patients more in treatment decisions, taking into account their preferences, lifestyle factors, and treatment goals. Patient support programs, educational resources, and self-management tools are being developed to empower patients and enhance treatment adherence.
-
Regulatory agencies are implementing guidelines and standards to ensure the safety and efficacy of atopic eczema treatments. Increased scrutiny of clinical trial data, post-marketing surveillance, and global harmonization of regulatory requirements are shaping drug development and approval processes, ensuring faster access to innovative treatments.
Competitive Landscape
The competitive landscape of the atopic eczema treatment market was dynamic, with several prominent companies competing to provide innovative and advanced atopic eczema treatment solutions.
- AbbVie Inc.
- Allergan plc
- Anacor Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol Myers Squibb
- Dermira, Inc.
- Eli Lilly and Company
- Galderma Laboratories
- GlaxoSmithKline plc
- Johnson & Johnson
- LEO Pharma A/S
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Sanofi
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Recent Developments:
January 24, 2024 — Merck Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology. Merck, a leading science and technology company, announced today that its Life Science business sector has signed a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech to explore collaboration in bringing innovative and high-capacity bioprocessing solutions to Taiwan and other international markets.
March 12, 2024 — Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma.
Regional Analysis
One such dominant region in the atopic eczema treatment market is North America, notably the United States. This prominence is underpinned by several key factors. Firstly, the United States exhibits a notably high prevalence of atopic eczema, with millions of individuals affected by the condition, thereby driving substantial demand for treatments and therapies. Moreover, North America boasts a sophisticated healthcare infrastructure, encompassing established pharmaceutical firms, renowned research institutions, and specialized dermatology healthcare facilities. This robust ecosystem fosters the development and commercialization of innovative atopic eczema treatments. Additionally, regulatory agencies in North America, such as the Food and Drug Administration (FDA) in the United States, play a pivotal role in streamlining the approval and market entry processes for new therapies. A favorable regulatory climate encourages increased investment in research and development efforts and accelerates the introduction of novel treatments, further reinforcing the region’s dominance in the atopic eczema treatment market.
Furthermore, heightened patient awareness and advocacy initiatives in North America contribute to greater diagnosis rates and heightened demand for effective treatments. Patient advocacy groups and support organizations actively raise awareness about atopic eczema, champion improved access to care, and drive forward research endeavors. In summary, North America, particularly the United States, emerges as a preeminent region in the atopic eczema treatment market, owing to its substantial patient population, advanced healthcare infrastructure, supportive regulatory environment, and robust research and development landscape. However, it is essential to acknowledge that other regions, such as Europe and Asia-Pacific, also wield significant influence in the global atopic eczema treatment market, each characterized by unique regional dynamics and opportunities.
Target Audience for Atopic Eczema Treatment Market
- Research and Development Teams
- Marketing Agencies
- Consulting Firms
- Research Institutions
- Regulatory Authorities
- Patient Advocacy Groups
- Medical Associations
- Health Insurance Companies
- Government Health Departments
- Market Research Firms
- Academic Institutions
Segments Covered in the Atopic Eczema Treatment Market Report
Atopic Eczema Treatment Market by Indication
- Topical
- Oral
- Injectable
Atopic Eczema Treatment Market by End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- Mail Order Pharmacies
- Dermatology Clinics
Atopic Eczema Treatment Market by Region
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Key Question Answered
- What is the expected growth rate of the Atopic Eczema Treatment market over the next 7 years?
- Who are the key market participants in Atopic Eczema Treatment, and what are their market share?
- What are the end-user industries driving market demand and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the Middle East, and Africa?
- How is the economic environment affecting the Atopic Eczema Treatment market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the Atopic Eczema Treatment market?
- What is the current and forecasted size and growth rate of the global Atopic Eczema Treatment market?
- What are the key drivers of growth in the Atopic Eczema Treatment market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the Atopic Eczema Treatment market?
- What are the technological advancements and innovations in the Atopic Eczema Treatment market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the Atopic Eczema Treatment market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the Atopic Eczema Treatment market?
- What are the product offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- ATOPIC ECZEMA TREATMENT MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON ATOPIC ECZEMA TREATMENT MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- ATOPIC ECZEMA TREATMENT MARKET OUTLOOK
- GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY INDICATION, 2020-2030, (USD BILLION)
- TOPICAL
- ORAL
- INJECTABLE
- GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY END USER, 2020-2030, (USD BILLION)
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- ONLINE PHARMACIES
- DRUG STORES
- MAIL ORDER PHARMACIES
- DERMATOLOGY CLINICS
- GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY REGION, 2020-2030, (USD BILLION)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*
(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)
- ABBVIE INC.
- AMGEN INC.
- ANACOR PHARMACEUTICALS, INC.
- ASTELLAS PHARMA INC.
- BAYER AG
- BRISTOL MYERS SQUIBB
- DERMIRA, INC.
- ELI LILLY AND COMPANY
- GALDERMA S.A.
- GLAXOSMITHKLINE PLC
- JOHNSON & JOHNSON
- LEO PHARMA A/S
- MITSUBISHI TANABE PHARMA CORPORATION
- NOVARTIS INTERNATIONAL AG
- PFIZER INC.
- REGENERON PHARMACEUTICALS, INC.
- SANOFI
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- UCB S.A.              *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 2 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 3 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY REGION (USD BILLION) 2020-2030
TABLE 4 NORTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 5 NORTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 6 NORTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 7 US ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 8 US ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 9 CANADA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 10 CANADA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 11 MEXICO ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 12 MEXICO ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 13 SOUTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 14 SOUTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 15 SOUTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 16 BRAZIL ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 17 BRAZIL ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 18 ARGENTINA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 19 ARGENTINA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 20 COLOMBIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 21 COLOMBIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 22 REST OF SOUTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 23 REST OF SOUTH AMERICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 24 ASIA-PACIFIC ATOPIC ECZEMA TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 25 ASIA-PACIFIC ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 26 ASIA-PACIFIC ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 27 INDIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 28 INDIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 29 CHINA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 30 CHINA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 31 JAPAN ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 32 JAPAN ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 33 SOUTH KOREA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 34 SOUTH KOREA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 35 AUSTRALIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 36 AUSTRALIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 37 SOUTH-EAST ASIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 38 SOUTH-EAST ASIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 39 REST OF ASIA PACIFIC ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 40 REST OF ASIA PACIFIC ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 41 EUROPE ATOPIC ECZEMA TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 42 EUROPE ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 43 EUROPE ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 44 GERMANY ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 45 GERMANY ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 46 UK ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 47 UK ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 48 FRANCE ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 49 FRANCE ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 50 ITALY ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 51 ITALY ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 52 SPAIN ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 53 SPAIN ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 54 RUSSIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 55 RUSSIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 56 REST OF EUROPE ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 57 REST OF EUROPE ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 58 MIDDLE EAST AND AFRICA ATOPIC ECZEMA TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030
TABLE 59 MIDDLE EAST AND AFRICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 60 MIDDLE EAST AND AFRICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 61 UAE ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 62 UAE ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 63 SAUDI ARABIA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 64 SAUDI ARABIA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 65 SOUTH AFRICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 66 SOUTH AFRICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
TABLE 67 REST OF MIDDLE EAST AND AFRICA ATOPIC ECZEMA TREATMENT MARKET BY INDICATION (USD BILLION) 2020-2030
TABLE 68 REST OF MIDDLE EAST AND AFRICA ATOPIC ECZEMA TREATMENT MARKET BY END USER (USD BILLION) 2020-2030
LIST OF FIGURES
FIGURE 1 MARKET DYNAMICS
FIGURE 2 MARKET SEGMENTATION
FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4 DATA TRIANGULATION
FIGURE 5 BOTTOM-UP APPROACH
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 RESEARCH FLOW
FIGURE 8 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY INDICATION, USD BILLION, 2022-2030
FIGURE 9 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY END USER, USD BILLION, 2022-2030
FIGURE 10 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY REGION, USD BILLION, 2022-2030
FIGURE 11 PORTER’S FIVE FORCES MODEL
FIGURE 12 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY INDICATION, USD BILLION,2022
FIGURE 13 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY END USER, USD BILLION, 2022
FIGURE 14 GLOBAL ATOPIC ECZEMA TREATMENT MARKET BY REGION, USD BILLION, 2022
FIGURE 15 MARKET SHARE ANALYSIS
FIGURE 16 ABBVIE INC.: COMPANY SNAPSHOT
FIGURE 17 AMGEN INC.: COMPANY SNAPSHOT
FIGURE 18 ANACOR PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
FIGURE 19 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
FIGURE 20 BAYER AG: COMPANY SNAPSHOT
FIGURE 21 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
FIGURE 22 DERMIRA, INC. : COMPANY SNAPSHOT
FIGURE 23 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 24 GALDERMA S.A.: COMPANY SNAPSHOT
FIGURE 25 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
FIGURE 26 JOHNSON & JOHNSON: COMPANY SNAPSHOT
FIGURE 27 LEO PHARMA A/S: COMPANY SNAPSHOT
FIGURE 28 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT
FIGURE 29 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
FIGURE 30 PFIZER INC.: COMPANY SNAPSHOT
FIGURE 31 REGENERON PHARMACEUTICALS, INC: COMPANY SNAPSHOT
FIGURE 32 SANOFI: COMPANY SNAPSHOT
FIGURE 33 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 35 UCB S.A.: COMPANY SNAPSHOT
FAQ
The global atopic eczema treatment market size is projected to grow from USD 12.48 billion in 2023 to USD 22.09 billion by 2030, exhibiting a CAGR of 8.5% during the forecast period.
North America accounted for the largest market in the atopic eczema treatment market.
AbbVie Inc., Allergan plc, Anacor Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Dermira, Inc.,Eli Lilly and Company, Galderma Laboratories, GlaxoSmithKline plc, Johnson & Johnson, LEO Pharma A/S,Merck & Co., Inc., Novartis AG.
There is growing awareness of atopic eczema’s impact on quality of life. Patient advocacy groups, professional societies, and healthcare organizations are working to raise awareness about the condition’s burden and advocate for improved access to effective treatments, research funding, and supportive care services.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.